Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • pre|CISIONTM
    • Pipeline
    • Partnering
    • News
  • Diagnostics
    • Diagnostics
    • What is an Affimer® ?
    • Key benefits
    • Applications
    • Custom Service
    • COVID-19
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • pre|CISIONTM
    • Pipeline
    • Partnering
    • News
  • Diagnostics
    • Diagnostics
    • What is an Affimer® ?
    • Key benefits
    • Applications
    • Custom Service
    • COVID-19
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

News

22 Dec 2020

Interview with Alastair Smith about license agreement with Astrea Bioseparations

Diagnostics | Investors
21 Dec 2020

License Agreement with Astrea Bioseparations

Diagnostics | Investors
23 Nov 2020

SARS-CoV-2 Rapid Antigen Test Update

Diagnostics | Investors
27 Oct 2020

ShareBuyers Interview with Alastair Smith

Diagnostics | Investors | Therapeutics
30 Sep 2020

Launch of SARS-CoV-2 BAMSTM Research Test

Diagnostics | Investors
29 Sep 2020

Interim Results for the Period Ended 30 June 2020 – webinar presentation

Investors
28 Sep 2020

Interim Results for the Period Ended 30 June 2020

Investors
14 Sep 2020

Notice of Results and Investor Presentation

Investors
07 Sep 2020

Alastair Smith gives more detail on the SARS-CoV-2 ELISA laboratory test

Diagnostics | Investors
07 Sep 2020

Avacta to Launch SARS-CoV-2 ELISA Laboratory Test

Diagnostics | Investors

Posts navigation

Older posts
Newer posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us
  • Avacta Animal Health

Avacta Life Sciences Ltd

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Cambridge

Unit B, 1 Lion Works
Station Road East
Whittlesford
Cambridge
CB22 4WL

virtual tour
email

FTI Consulting

200 Aldersgate
Aldersgate Street
London
EC1A 4HD

+44 (0)20 3727 1000

email

Twitter | Linkedin

©2021 Avacta Life Sciences Limited. Registered company no. 06605196. Affimer® is a registered trade mark.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok